Key facts
- This page summarizes Adrienne Farid's Form 4 filing for Century Therapeutics, Inc. (IPSC).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Mar 2025, 19:27.
Adrienne Farid - 10 Mar 2025 Form 4 Insider Report for Century Therapeutics, Inc. (IPSC)
- Reporting relationship
- Chief Operations Officer
- Issuer ticker
- IPSC
- Reported as of
- 10 Mar 2025
- Net transaction value
- -$1,451
- SEC form
- 4
- Accepted by SEC
- 12 Mar 2025, 19:27:03 UTC
- Prior SEC filing
- 05 Feb 2025
- Next SEC filing
- 07 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Douglas Carr, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Adrienne Farid filed Form 4 for Century Therapeutics, Inc. (IPSC) on 12 Mar 2025.
Change
- Previous filing in this sequence was filed on 05 Feb 2025.
- Current net transaction value: -$1,451.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IPSC
transaction
Common Stock
Sale
- Transaction value
- $1,451
- Shares
- -2,359
- Change %
- -1.8%
- Price
- $0.6150
- Shares after
- 131,717
- Date
- 10 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
IPSC
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +120,000
- Change %
- +91%
- Price
- $0.000000
- Shares after
- 251,717
- Date
- 11 Mar 2025
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IPSC
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +120,000
- Change %
- Price
- $0.000000
- Shares after
- 120,000
- Date
- 11 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 120,000
- Exercise price
- $0.6010
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). Such sales were automatic and not at the discretion of the Reporting Person.
Footnote F2
Reflects the grant of RSUs. Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on March 11, 2026, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
Footnote F3
The option vests 25% on March 11, 2026, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.